European Investor
07 May 2026, 17:22
BD Jumps 6% as Clean Quarter, EPS Raise, and Post-Spin Clarity Win Over Investors
Franklin Lakes, May 7, 2026 — Shares in Becton, Dickinson and Company rose around 6% today after the medical technology company delivered a second fiscal quarter that beat expectations across revenue, margins, and earnings, then raised its full-year adjusted EPS guidance — a combination that gave investors the reassurance they needed following a period of significant corporate restructuring.
BD reported Q2 fiscal 2026 revenues of $4.714 billion, up 5.2% year-over-year or 2.6% on a foreign currency neutral basis. Adjusted diluted EPS came in at $2.90, up 3.9% from $2.79 in the prior year period and ahead of internal expectations. The GAAP EPS was a loss of $0.13, reflecting charges tied to the company's recently completed spin-off of its Biosciences and Diagnostic Solutions business, which was combined with Waters Corporation in February 2026. Investors have largely set aside GAAP noise in the post-spin period and are focused on the underlying continuing operations.
The breadth of the performance impressed. CEO Tom Polen noted that more than 90% of the business delivered mid-single-digit growth, with the Interventional segment leading the way at 7.3% reported growth and 5.3% on a currency neutral basis. Connected Care grew 4.9% and Medical Essentials 4.7%. BioPharma Systems was the one soft spot, growing just 2.5% reported and contracting slightly on a currency neutral basis.
The capital allocation moves added to the positive sentiment. BD executed a $2 billion accelerated share repurchase program and retired $2.1 billion of debt during the quarter — a substantial deleveraging effort that signals management's confidence in the business's cash generation and strengthens the balance sheet profile of the leaner, post-spin company.
Full-year adjusted diluted EPS guidance was raised to $12.52 to $12.72, up from the prior range of $12.35 to $12.65, while revenue growth guidance was reaffirmed. For a company still in the early stages of repositioning after a major strategic separation, the combination of execution, capital discipline, and raised guidance was enough to send the stock meaningfully higher.
Franklin Lakes, May 7, 2026 — Shares in Becton, Dickinson and Company rose around 6% today after the medical technology company delivered a second fiscal quarter that beat expectations across revenue, margins, and earnings, then raised its full-year adjusted EPS guidance — a combination that gave investors the reassurance they needed following a period of significant corporate restructuring.
BD reported Q2 fiscal 2026 revenues of $4.714 billion, up 5.2% year-over-year or 2.6% on a foreign currency neutral basis. Adjusted diluted EPS came in at $2.90, up 3.9% from $2.79 in the prior year period and ahead of internal expectations. The GAAP EPS was a loss of $0.13, reflecting charges tied to the company's recently completed spin-off of its Biosciences and Diagnostic Solutions business, which was combined with Waters Corporation in February 2026. Investors have largely set aside GAAP noise in the post-spin period and are focused on the underlying continuing operations.
The breadth of the performance impressed. CEO Tom Polen noted that more than 90% of the business delivered mid-single-digit growth, with the Interventional segment leading the way at 7.3% reported growth and 5.3% on a currency neutral basis. Connected Care grew 4.9% and Medical Essentials 4.7%. BioPharma Systems was the one soft spot, growing just 2.5% reported and contracting slightly on a currency neutral basis.
The capital allocation moves added to the positive sentiment. BD executed a $2 billion accelerated share repurchase program and retired $2.1 billion of debt during the quarter — a substantial deleveraging effort that signals management's confidence in the business's cash generation and strengthens the balance sheet profile of the leaner, post-spin company.
Full-year adjusted diluted EPS guidance was raised to $12.52 to $12.72, up from the prior range of $12.35 to $12.65, while revenue growth guidance was reaffirmed. For a company still in the early stages of repositioning after a major strategic separation, the combination of execution, capital discipline, and raised guidance was enough to send the stock meaningfully higher.
